List of Excipients in Branded Drug ATORVASTATIN CALCIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	ATORVASTATIN CALCIUM	atorvastatin calcium	42254-019	CALCIUM CARBONATE
Rebel Distributors Corp	ATORVASTATIN CALCIUM	atorvastatin calcium	42254-019	CANDELILLA WAX
Rebel Distributors Corp	ATORVASTATIN CALCIUM	atorvastatin calcium	42254-019	CELLULOSE, MICROCRYSTALLINE

Generic Drugs Containing ATORVASTATIN CALCIUM

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	atorvastatin calcium	0093-5056	CALCIUM CARBONATE
Teva Pharmaceuticals USA Inc	atorvastatin calcium	0093-5056	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	atorvastatin calcium	0093-5056	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in ATORVASTATIN CALCIUM?

# Of NDCs	Excipient
56	ANHYDROUS LACTOSE
6	ARGININE
1	CALCITE

Excipient Strategy for Atorvastatin Calcium

Last updated: February 25, 2026

A comprehensive excipient strategy for atorvastatin calcium involves selecting excipients that enhance drug stability, bioavailability, and manufacturing efficiency. The goal is to optimize formulation performance while minimizing potential adverse interactions.

Key Considerations in Excipient Selection

• Drug Physicochemistry: Atorvastatin calcium is poorly water-soluble, classifying it as a BCS Class II compound. This necessitates excipients that improve solubility and dissolution.
• Stability: The active ingredient is sensitive to hydrolysis and oxidation, requiring stabilizers and protective excipients.
• Manufacturing: Compatibility with process methods like direct compression or wet granulation influences excipient choice.
• Patient Compliance: Taste masking and tablet disintegration impact patient acceptability.

Core Excipient Categories and Functions

Solubilizers and Disintegrants

• Polyethylene glycol (PEG): Enhances solubility; used as a solvent or in solid dispersions.
• Sodium bicarbonate: Creates a local alkaline environment to increase solubility, particularly in suspension formulations.
• Croscarmellose sodium or sodium starch glycolate: Facilitates rapid disintegration in tablets.

Binders and Fillers

• Microcrystalline cellulose (MCC): Provides structural integrity, compressibility, and disintegration properties.
• Lactose monohydrate: Acts as a filler; suitable for direct compression.
• Mannitol: Used for its sweet taste and as a filler, especially in chewable formulations.

Stabilizers and Protectants

• Antioxidants (e.g., ascorbic acid, sodium bisulfite): Protect against oxidative degradation.
• Chelating agents (e.g., EDTA): Bind metal ions that catalyze oxidation.

Coating Agents

• Hydroxypropyl methylcellulose (HPMC): Forms protective film coatings that control release and improve stability.
• Polyvinyl alcohol (PVA): Used in film coating to mask taste and provide stability.

Formulation Strategy Summary

Excipient Category	Purpose	Example Agents	Considerations
Solubilizers	Improve bioavailability	PEG 4000, sodium bicarbonate	Compatibility with atorvastatin; avoid excessive alkalinity
Disintegrants	Ensure rapid tablet breakup	Croscarmellose sodium	Concentration optimized for tablet hardness
Binders	Provide cohesion	MCC, povidone	Must not interfere with dissolution
Fillers	Add bulk, aid processing	Lactose, mannitol	Consider tolerability and taste
Stabilizers	Prevent degradation	Ascorbic acid, EDTA	Concentration balanced to avoid stability issues
Film Coatings	Protect from environmental factors	HPMC, PVA	Achieve desired release profile

Regulatory and Quality Considerations

• All excipients must meet pharmacopeial standards (USP, EP).
• Compatibility testing with atorvastatin calcium is essential to prevent adverse interactions.
• Stability studies should evaluate excipient impact under accelerated and long-term conditions.
• Regulatory filings should detail excipient sources, grades, and functions.

Conclusion

An effective excipient strategy for atorvastatin calcium balances solubility enhancement, stability, manufacturability, and patient compliance. Selection hinges on compatibility with process, regulatory standards, and formulation goals.

Key Takeaways

• The primary challenge is improving solubility of a BCS Class II drug.
• Stabilizers and antioxidants are crucial to prevent oxidation and hydrolysis.
• Disintegrants and fillers must support rapid dissolution and ease of manufacturing.
• Regulatory compliance and thorough compatibility testing underlie excipient choices.

FAQs

1. What excipients are best suited for solubility enhancement in atorvastatin formulations?
Polyethylene glycol and sodium bicarbonate are common choices for increasing solubility and dissolution rates.

2. How do stabilizers benefit atorvastatin calcium formulations?
They mitigate oxidative and hydrolytic degradation, extending shelf life and ensuring efficacy.

3. Can taste masking be achieved with excipients in atorvastatin tablets?
Yes, film coatings with HPMC or PVA can mask bitterness and improve patient acceptance.

4. What role do disintegrants play in tablet formulations?
Disintegrants like croscarmellose sodium facilitate rapid tablet break-up, improving dissolution and absorption.

5. Are there any specific excipients to avoid with atorvastatin calcium?
Excipients that induce interactions, such as strong chelating agents beyond testing scope, should be avoided to prevent stability issues.

---

References

[1] United States Pharmacopeia. (2022). USP-NF 45. United States Pharmacopeial Convention.

[2] European Pharmacopoeia. (2022). EDQM.
[3] Li, H., & Johnston, T. P. (2005). "Suppression of Oxidation of Atorvastatin." Journal of Pharmaceutical Sciences, 94(5), 1044–1052.